291 related articles for article (PubMed ID: 29733447)
1. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.
Kankam M; Hall J; Gillen M; Yang X; Shen Z; Lee C; Liu S; Miner JN; Walker S; Clauson V; Wilson D; Nguyen M
J Clin Pharmacol; 2018 Sep; 58(9):1214-1222. PubMed ID: 29733447
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers.
Hall J; Gillen M; Yang X; Shen Z
Clin Pharmacol Drug Dev; 2019 Feb; 8(2):179-187. PubMed ID: 29688628
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects.
Hall J; Gillen M; Liu S; Miner JN; Valdez S; Shen Z; Lee C
Drug Des Devel Ther; 2018; 12():1799-1807. PubMed ID: 29950814
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.
Shen Z; Gillen M; Miner JN; Bucci G; Wilson DM; Hall JW
Drug Des Devel Ther; 2017; 11():2077-2086. PubMed ID: 28744099
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials.
Fitz-Patrick D; Roberson K; Niwa K; Fujimura T; Mori K; Hall J; Yan X; Shen Z; Liu S; Ito Y; Baumgartner S
Mod Rheumatol; 2019 Nov; 29(6):1042-1052. PubMed ID: 30334639
[No Abstract] [Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non-Asian participants.
Johansson S; Han D; Hunt T; Björck K; Florica D; Gillen M; Hall J; Erlandsson F
Pharmacol Res Perspect; 2022 Jun; 10(3):e00929. PubMed ID: 35593744
[TBL] [Abstract][Full Text] [Related]
7. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study.
Fleischmann R; Winkle P; Miner JN; Yan X; Hicks L; Valdez S; Hall J; Liu S; Shen Z; Gillen M; Hernandez-Illas M
RMD Open; 2018; 4(1):e000584. PubMed ID: 29531784
[TBL] [Abstract][Full Text] [Related]
9. Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
Stack AG; Han D; Goldwater R; Johansson S; Dronamraju N; Oscarsson J; Johnsson E; Parkinson J; Erlandsson F
J Clin Endocrinol Metab; 2021 Apr; 106(5):e2347-e2356. PubMed ID: 33075806
[TBL] [Abstract][Full Text] [Related]
10. A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases.
Leander J; Sunnåker M; Rekić D; Aksenov S; Eriksson UG; Johansson S; Parkinson J
J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):525-541. PubMed ID: 33728547
[TBL] [Abstract][Full Text] [Related]
11. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Rheumatology (Oxford); 2012 Sep; 51(9):1670-6. PubMed ID: 22539486
[TBL] [Abstract][Full Text] [Related]
12. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
[TBL] [Abstract][Full Text] [Related]
13. Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.
Stack AG; Dronamraju N; Parkinson J; Johansson S; Johnsson E; Erlandsson F; Terkeltaub R
Am J Kidney Dis; 2021 Apr; 77(4):481-489. PubMed ID: 33130235
[TBL] [Abstract][Full Text] [Related]
14. An audit of a therapeutic drug monitoring service for allopurinol therapy.
Kannangara DR; Ramasamy SN; Ray JE; Jones G; Graham GG; Williams KM; Day RO
Ther Drug Monit; 2013 Dec; 35(6):863-6. PubMed ID: 24263644
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
Baumgartner S; Yeh LT; Shen Z; Kerr B; Manhard K; Quart B
J Clin Pharmacol; 2018 Sep; 58(9):1164-1170. PubMed ID: 29733441
[TBL] [Abstract][Full Text] [Related]
16. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
[TBL] [Abstract][Full Text] [Related]
17. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
18. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Merriman TR; Wright DFB; Drake J; Dalbeth N
Clin Transl Sci; 2020 Jan; 13(1):110-115. PubMed ID: 31444839
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
Fleischmann R; Kerr B; Yeh LT; Suster M; Shen Z; Polvent E; Hingorani V; Quart B; Manhard K; Miner JN; Baumgartner S;
Rheumatology (Oxford); 2014 Dec; 53(12):2167-74. PubMed ID: 24509406
[TBL] [Abstract][Full Text] [Related]
20. Predicting allopurinol response in patients with gout.
Wright DF; Duffull SB; Merriman TR; Dalbeth N; Barclay ML; Stamp LK
Br J Clin Pharmacol; 2016 Feb; 81(2):277-89. PubMed ID: 26451524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]